Press Releases
Page 1 of 26
Onxeo reports its financial results for the first half of 2020 and provides an update on its activities
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]
09/17/2020
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
09/08/2020
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]
Tags: AsiDNA™
09/03/2020
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
Tags: AsiDNA™
08/27/2020
Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility
Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
07/29/2020
Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Tags: Financials & Corporate
07/03/2020
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties
Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Tags: OX401
06/25/2020
New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
Tags: AsiDNA™
06/22/2020
Onxeo: report on the Extraordinary General Meeting of June 19, 2020
Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Tags: Financials & Corporate
06/19/2020
Boursoroma – Judith Greciet, Onxeo : «AsiDNA could open a new paradigm in cancer treatment»
Read the interview
Tags: AsiDNA™
06/17/2020
Page 1 of 26